Printer Friendly

Detection of point mutation in Plasmodium falciparum ATPase6 gene associated with artemisinin resistance from Assam and Arunachal Pradesh.

INTRODUCTION

Artemisinin and its derivatives are most effective antimalarial drugs which act upon by selectively inhibiting Plasmodium falciparum ATPase6 protein, the only SERCA-type [Ca.sup.2+] ATPase in the P. falciparum genome, believed to be the primary target for artemisinins. In 2001, the World Health Organization (WHO) recommended the use of artemisinin-based combination therapy (ACT), in which a long-acting partner is added to artemisinin to make it more effective, as first-line treatment for uncomplicated P. falciparum malaria in all malaria endemic countries (1). Five combinations currently recommended by the WHO for uncomplicated P. falciparum malaria cases are artemether-lumefantrine (AM-LF), artesunatemefloquine (AS-MQ), artesunate-sulfadoxine-pyrimethamine (AS-SP), dihydroartemisinin-piperaquine, and artesunate amodiaquine (2). Many countries are now starting to implement this regime (3-11). However, AS-SP combination is being widely used in many of the countries (1, 11-14). Further, certain mutations in P. falciparum ATPase (6) are detected and are found to be associated with artemisinin resistance in some countries (8, 15-16). There are few molecular markers which are believed to reduce parasite sensitivity (8, 15-16). It has been established in several studies that serine to asparagine mutation at codon 769 in P. falciparum ATPase6 gene is associated with raised artemether half maximal inhibitory concentration ([IC.sub.50]), and suggested that the mutation may be used as a molecular marker for monitoring artemisinin resistance (8). The combination of two additional single nucleotide polymorphisms (SNPs), E431K and A623E was defined in fresh isolates from Senegal with increased [IC.sub.50] to artemether (8). Besides this, it has been suggested that the mutations at codon L263E are associated with artemisinin resistance (8, 15-16). The increase in P. falciparum multidrug resistance-1 copy number is also believed to reduce parasite sensitivity to some quinoline antimalarials (typically an aminoquinoline) the partner drug of ACT (17-18). However, artesunate resistance has not yet been reported from India (1). Due to the prevalence of high level of resistance in partner drug of ACT in P. falciparum field isolates from northeastern part of India (19-22), it is assumed that PfATPase6 genotype could make early warning signals for emergence of ACT resistance.

MATERIAL & METHODS

The study was conducted in different malaria endemic areas of Assam and Arunachal Pradesh during the period from January 2012 to February 2014 (Fig. 1). Two millilitre of blood sample was collected from malaria suspected patients (before treatment) irrespective of age, sex and disease severity. Prior to collection of blood samples, a concise enlightenment was given to the participants about the purpose of the study. Simultaneously consent was taken from each participant. In case of children, informed consent was provided by their guardians. Human ethical clearance was obtained from the Institutional Ethical Board of the Regional Medical Research Centre (RMRC), ICMR, Dibrugarh. After collecting blood samples, microscopic slide examination was done as a gold standard for laboratory confirmation of malaria and species identification. Parasite counts were done by Giemsa staining and the number of asexual parasites against 200 WBC was counted in 100 x microscopic fields, assuming an average of WBC count 8,000/[micro]l. Parasitaemia was calculated and expressed as percentage. Genomic DNA was extracted from 200 pl of whole blood by using QIAamp DNA mini kit as per manufacturer's instruction (Qiagen, Hilden, Germany). Initially, a 1793 bp fragment spanning the coding region of exon 1 of the PfATPase6 gene was amplified by primary polymerase chain reaction (PCR). The primary amplification was performed by using the oligonucleotide primers PfATPase6P1 and PfATPase6-P2 as described elsewhere (4) in a reaction mixture of total volume 20 [micro]l which consisted of 5 pl of genomic DNA, 4 [micro]l of 5 x colourless Gotaq reaction buffer, 0.3 [micro]M (0.6 [micro]l in 20 [micro]l of reaction volume) of each primer, 0.2 mM (0.165 [micro]l in 20 [micro]l of reaction volume) of each deoxyribonucleoside triphosphate (dATP, dTTP, dGTP, dCTP) and 1.2 units of taq DNA polymerase (0.24 [micro]l in 20 [micro]l of reaction volume). Amplification was performed under the following conditions: initial denaturation at 94[degrees]C for 3 min, followed by 35 cycles of denaturation at 94[degrees]C for 45 sec, annealing at 47[degrees]C for 1 min, and extension at 72[degrees]C for 1 min and a final extension period at 72[degrees]C for 10 min. In the nested reaction, a 645 bp fragment was amplified from the primary amplicons. The nested amplification was done by using the oligonucleotide primers PfATPase6-N1 and PfATPase6-N2 as described elsewhere (23) in a total volume 50 [micro]l consisted of 3 [micro]l of primary PCR product, 10 [micro]l of 5 x colourless Gotaq reaction buffer, 0.3 [micro]M (1.5 [micro]l in 50 [micro]l of reaction volume) of each primer, 0.2 mM (0.45 [micro]l in 50 [micro]l of reaction volume) of each deoxyribonucleosannualtide triphosphate (dATP, dTTP, dGTP, dCTP), 0.48 units of taq DNA polymerase (0.24 [micro]l in 50 [micro]l of reaction volume) and 1 mM of Mg[Cl.sub.2] (2 [micro]l in 50 [micro]l of reaction volume). The reaction settled with an initial hold (94[degrees]C/3 min), 40 cycles (94[degrees]C/1 min, 51[degrees]C/1 min, 72[degrees]C/1 min and 72[degrees]C/10 min). The amplified products were further purified before sequencing and the sequencing products were edited in BioEdit software and aligned through ClustalW in Mega 5 software. Single nucleotide polymorphisms were analysed in DnaSP software version v.5.10.01.

[FIGURE 1 OMITTED]

RESULTS & DISCUSSION

A partial fragment of PfATPase6 gene, believed to be a target for the artemisinin drugs was amplified and sequenced in 141 P. falciparum positive samples from malaria endemic areas of Assam and Arunachal Pradesh (Fig. 1). The nucleotide sequences were submitted to National Centre for Biotechnology Information (NCBI) gene bank data base and accession numbers obtained afterwards (KJ510660-KJ510800). The nucleotide sequences were analysed for detection of single nucleotide polymorphisms in PfATPase6 gene. Novel non-synonymous mutation (C-T) at 1847 bp position of PfATPase6 gene that leads serine to phenylalanine alteration at codon S616F was observed in 3.55% P. falciparum field isolates. The mutant S616F allele was detected only in the P. falciparum field isolates in Changlang district of Arunachal Pradesh, however, this mutant genotype was not observed in any other parts of the study area.

The mutations at codon S769N, which have been proposed to confer artemisinin resistance were not detected from the analyzed samples. A number of molecular studies have been carried out in different countries for detection of point mutation in PfATPase6 gene that was believed to be the main target of artemisinins. Previous study conducted in French Guyana confirmed the existence of S769N or L263E mutant alleles in the P. falciparum field isolate (8, 15-16). Reduced efficacy of the AS-MQ combination therapy and in vitro resistance to AS have also been reported on the Thai-Cambodia border and in western Cambodia, respectively (3, 24-25). Although in our study, no SNP's were detected in any of the analyzed samples from Assam, but five numbers of P. falciparum field samples in Changlang district of Arunachal Pradesh showed novel non-synonymous mutation (C-T) at 1847 bp position of PfATPase6 gene. Further evidence regarding this mutation is not available from any part of the world, whether this mutation is associated with artemisinin resistance or not. In previous consequence, non-synonymous mutations were detected at codons E431K, K649E and N683K, and synonymous mutations were noted at codons G468G, N483N and I898I in PfATPase6 gene from P. falciparum isolates in tea garden areas of Jalpaiguri district, India (1). However, future studies will provide a hint regarding the role of this mutation with artemisinin resistance/sensitivity.

Based upon the mutational pattern, two haplotypes of PfATPase6 gene were observed during the study period. The wild type haplotype was circulating in Assam, whereas the mutant S616F allele was predominant in Changlang district of Arunachal Pradesh. The overall haplotype diversity (Hd) was: 0.069, whereas the overall nucleotide diversity (per site Pi) was 0.00012. Highest haplotype diversity was recorded in Changlang district of Arunachal Pradesh having Hd value of 0.33333 along with single polymorphic site and nucleotide diversity (Pi): 0.00060. High value of haplotype diversity indicates the high probability that two randomly chosen haplotypes are different. No significant haplotype diversity and genetic differentiation was observed among the P. falciparum field isolates in Karbi Anglong, Chirang, Tinsukia, Sivasagar, Jorhat, NC Hills, Lakhimpur, Golaghat and Dibrugarh districts of Assam and Lohit district of Arunachal Pradesh with a value of Hd: 0.00000. The population genetic structure was determined within the parasite population of Assam and Arunachal Pradesh. The parasite population of Changlang in comparison to any of other district had a pair-wise fixation index (FST) value of 0.16667 indicating great genetic differentiation within the population (26). This greater genetic distance value within populations indicates some isolation between parasite population and most likely mean that the populations are not currently breeding with one another. Conventionally, the Nm: 1.25 signifies that there is sufficient gene flow between localities to negate the effects of genetic drift. The overall values of neutrality test are given in Table 1. The negative values of Tajima's D indicate an excess of low frequency alleles relative to expectation that can result to population expansions or positive selection. However, as these values are not statistically significant, we cannot ascribe that these allelic frequencies lead to the outcome of population expansion.

The combination of AS+SP was introduced by Government of India since 2010 as the first line agent to treat all diagnosed uncomplicated P. falciparum malaria (1, 4). Now-a-days, AS + SP remains efficacious for the treatment of P. falciparum across diverse sites in central and eastern India. Although, Government of India has supplied ACT (AS+SP) combination for treatment purpose but due to the occurrence of high grade of sulfadoxine-pyrimethamine resistance (SPR) malaria parasite from northeastern parts of India, it should be a reason of concern because the life-span of ACTs depend largely on the partner drug, and any pre-existing resistance to SP could endanger the new combination. Since pre-existing resistance to SP exists in India, especially along the border with Myanmar where reduced artemisinin sensitivity has been reported, constant monitoring of the efficacy of ACT is essential in this aspect (3, 19-21).

CONCLUSION

Novel mutations at codon position 616 in P. falciparum ATpase6 gene was detected from the field isolates in Changlang district of Arunachal Pradesh. In Assam the wild type PfATPase6 genotype is found to circulate which indicates that the use of ACT is still effective for treatment of P. falciparum cases. Continuous in vitro assays as well as clinical efficacy trials along with molecular study can facilitate to monitor drug sensitivity which helps to confer early warning signal of an impending ACT resistance.

REFERENCES

(1.) Saha P, Guha SK, Das S, Mullick S, Ganguly S, Biswas A, et al. Comparative efficacies of Artemisinin combination therapies in Plasmodium falciparum malaria and polymorphism of PfATPase6, pfcrt, pfdhfr and pfdhps genes in tea gardens of Jalpaiguri district. Antimicrobial Agents Chemother 2012; 56(5): 2511-7.

(2.) World malaria report 2010. Geneva, Switzerland: World Health Organization 2010; p. 1-220.

(3.) Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361(5): 455-67.

(4.) National Drug Policy on Malaria 2010. http://nvbdcp.gov.in/ Doc/drug-policy-2010.pdf. accessed on 01/03/2014

(5.) Denis MB, Tsuyuoka R, Poravuth Y, Narann TS, Seila S, Lim C, et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 2006; 11: 1360-6.

(6.) Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. International artemisinin study group--Artesunate combinations for treatment of malaria: Meta analysis. Lancet 2004; 363: 9-17.

(7.) Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, et al. Artemether lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: A randomized trial to guide policy in Uganda. PLoS One 2008; 3: 2390.

(8.) Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B. Resistance of Plasmodium falciparum field isolates to in vitro artemether and point mutations of the SERCA-type PfATpase6. Lancet 2005; 366 (99501): 1960-3.

(9.) Valecha N, Srivastava P, Mohanty SS, Mitra P, Sharma SK, Tyagi PK, et al. Therapeutic efficacy of artemether-lumefantrine in uncomplicated falciparum malaria in India. Malar J 2009; 8: 107.

(10.) Sirima SB, Gansane A. Artesunate-amodiaquine for the treatment of uncomplicated malaria. Expert Opin Invest Drugs 2007; 16(7): 1079-85.

(11.) Djalle D, Njuimo SP, Manirakiza A, Laganier R, Le Faou A, Rogier C. Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: A randomized trial. Malar J 2014; 13: 9.

(12.) Marquino W, Ylquimiche L, Hermenegildo Y, Palacios AM, Falcon! E, Cabezas C, et al. Efficacy and tolerability of artesunate plus sulfadoxine-pyrimethamine and sulfadoxine-py rimethamine alone for the treatment of uncomplicated Plasmodium falciparum malaria in Peru. Am J Trop Med Hyg 2005; 72(5): 568-72.

(13.) Elamin SB, Malik EM, Abdelgadir T, Khamiss AH, Mohammed MM, Ahmed ES, et al. Artesunate plus sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in Sudan. Malar J 2005; 4: 41.

(14.) World malaria report 2008. Geneva: World Health Organization 2008; p. 1-190.

(15.) Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003; 424: 957-61.

(16.) Uhlemann AC, Cameron A, Eckstein-Ludwig U, Fischbarg J, Iserovich P, Zuniga FA, et al. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat Struct Mol Biol 2005; 12: 628-9.

(17.) Price RN, Cassar C, Brockman A, Duraisingh M, Van Vugt M, White NJ, et al. The Pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother 1999; 43(12): 2943-9.

(18.) Duraisingh MT, Cowman AF. Contribution of the Pfmdr1 gene to antimalarial drug-resistance. Acta Trop 2005; 94: 181-90.

(19.) Ahmed A, Das MK, Dev V, Saifi MA, Wajihullah, Sharma YD. Quadruple mutations in dihydrofolate reductase of Plasmodium falciparum isolates from Car Nicobar Island, India. Antimicrob Agents Chemother 2006; 50: 1546-9.

(20.) Ahmed A, Bararia D, Vinayak S, Yameen M, Biswas S, Dev V, et al. Plasmodium falciparum isolates in India exhibit a progressive increase in mutations associated with sulphadoxine-pyrimethamine resistance. Antimicrob Agents Chemother 2004; 48: 879-89.

(21.) Ahmed A, Lumb V, Das MK, Dev V, Wajihullah, Sharma YD. Prevalence of mutations associated with higher levels of sulphadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Car Nicobar Island and Assam, India. Antimicrob Agents Chemother 2006; 50: 3934-8.

(22.) Sharma YD. Molecular surveillance of drug-resistant malaria in India. Curr Sci 2012; 102 (5): 696-703.

(23.) Tahar R, Ringwald P, Basko LK. Molecular epidemiology against clinical isolates of P. falciparum and sequence analysis of the P. falciparum ATPase6 gene. Am J Trop Med Hyg 2009; 81(1): 13-8.

(24.) Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359: 2619-20.

(25.) Vijaykadga S, Rojanawatsirivej C, Cholpol S, Phoungmanee D, Nakavej A, Wongsrichanalai C. In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health 2006; 11: 211-9.

(26.) Hudson RR, Slatkin M, Maddison WP. Estimation of levels of gene flow from DNA sequence data. Genetics 1992; 132(2): 583-9.

Jitendra Sharma, Prafulla Dutta, S.A. Khan, Monika Soni & Jagadish Mahanta

Entomology and Filariasis Division, Regional Medical Research Centre (ICMR), North East Region, Dibrugarh, India

Correspondence to: Jitendra Sharma, Entomology and Filariasis Division, Regional Medical Research Centre (ICMR), North East Region, Dibrugarh-786 001, Assam, India.

E-mail: jitendra.du.biotech@gmail.com

Received: 8 April 2014

Accepted in revised form: 16 July 2014
Table 1. Value of neutrality tests and their significance

Neutrality        Value      Statistical significance
test

Tajima's D        -0.66531   Non-significant (p > 0.10)
Fu and Li's D     0.47228    Non-significant (p > 0.10)
test statistics

Fu and Li's F     0.14604    Non-significant (p > 0.10)
test statistics

Fu's Fs           -0.782
statistics

Strobeck's        0.947
S statistics
COPYRIGHT 2014 Indian Council of Medical Research
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Sharma, Jitendra; Dutta, Prafulla; Khan, S.A.; Soni, Monika; Mahanta, Jagadish
Publication:Journal of Vector Borne Diseases
Article Type:Report
Geographic Code:9INDI
Date:Dec 1, 2014
Words:2731
Previous Article:Identification of risk factors for malaria control by focused interventions in Ranchi district, Jharkhand, India.
Next Article:Artemisia vulgaris L. ethanolic leaf extract reverses thrombocytopenia/ thrombocytosis and averts end-stage disease of experimental severe Plasmodium...
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters